Patents by Inventor Sam Zaremba
Sam Zaremba has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20150161702Abstract: Provided herein is a method and computer program product for designing and/or simulating a biotechnology experiment in silico; and for providing and generating revenue from a customized list of one or more biotechnology products and/or services related to the in silico designed or simulated biotechnology experiment or the product of that experiment. In illustrative examples, the products and or services are indirectly related to a biomolecule designed by the in silico designed biotechnology experiment. In addition, provided herein is a method and computer system for generating revenue, that includes providing a customer with a first computer program product for designing or performing a biotechnology experiment in silico; and providing the customer with access to a purchase function for purchasing a second computer program product for designing or performing a biotechnology experiment in silico.Type: ApplicationFiled: April 30, 2014Publication date: June 11, 2015Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Shao-Min YUAN, Michael Beltsov, Thomas Chappell, Kevin Clancy, Peter McGarvey, Sam Zaremba, James Caffrey, Konstantin Belov, Anatoliy Mnev, Siamak Baharloo, Aruna Myneni, James Gilmore
-
Patent number: 8609395Abstract: The invention provides a polypeptide comprising an agonist of a MHC Class I binding native sequence having amino acid substitution(s) and enhanced immunogenicity compared to the native sequence. The invention provides DNA encoding the polypeptide, as well as vectors and cells comprising the DNA and methods comprising the administration of the polypeptide.Type: GrantFiled: February 17, 2012Date of Patent: December 17, 2013Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Jeffrey Schlom, Elene Barzaga, Sam Zaremba
-
Publication number: 20120221432Abstract: Provided herein is a method and computer program product for designing and/or simulating a biotechnology experiment in silico; and for providing and generating revenue from a customized list of one or more biotechnology products and/or services related to the in silico designed or simulated biotechnology experiment or the product of that experiment. In illustrative examples, the products and or services are indirectly related to a biomolecule designed by the in silico designed biotechnology experiment. In addition, provided herein is a method and computer system for generating revenue, that includes providing a customer with a first computer program product for designing or performing a biotechnology experiment in silico; and providing the customer with access to a purchase function for purchasing a second computer program product for designing or performing a biotechnology experiment in silico.Type: ApplicationFiled: June 1, 2010Publication date: August 30, 2012Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Shao-Min Yuan, Michael Beltsov, Thomas G. Chappell, Kevin Clancy, Peter McGarvey, Sam Zaremba, James Caffrey, Konstantin Belov, Anatoliy Mnev, Siamak BAHARLOO, Aruna Myneni, James Gilmore
-
Publication number: 20120149102Abstract: The invention provides a polypeptide comprising an agonist of a MHC Class I binding native sequence having amino acid substitution(s) and enhanced immunogenicity compared to the native sequence. The invention provides DNA encoding the polypeptide, as well as vectors and cells comprising the DNA and methods comprising the administration of the polypeptide.Type: ApplicationFiled: February 17, 2012Publication date: June 14, 2012Applicants: Human ServiceInventors: Jeffrey Schlom, Elene Barzaga, Sam Zaremba
-
Patent number: 8178508Abstract: The invention provides a prostate specific antigen oligo-epitope peptide (PSA-OP) that is useful as an immunogen in the prevention or treatment of prostatic cancer and in the inhibition of prostatic cancer cells and in the establishment and characterization of PSA-specific cytotoxic T-cell lines. In particular, the invention provides methods for eliciting an immune response against PSA comprising administering (i) a priming inoculation of a first recombinant virus encoding PSA-OP and (ii) one or more boosting inoculations of a second recombinant virus encoding PSA-OP, wherein the first and second recombinant viruses are from a different genus.Type: GrantFiled: December 23, 2010Date of Patent: May 15, 2012Assignee: The United States of America as represented by the Secretary, Department of Health and Human ServicesInventors: Jeffrey Schlom, Kwong-Yok Tsang, Sam Zaremba
-
Publication number: 20110091498Abstract: The invention provides a prostate specific antigen oligo-epitope peptide (PSA-OP) that is useful as an immunogen in the prevention or treatment of prostatic cancer and in the inhibition of prostatic cancer cells and in the establishment and characterization of PSA-specific cytotoxic T-cell lines. In particular, the invention provides methods for eliciting an immune response against PSA comprising administering (i) a priming inoculation of a first recombinant virus encoding PSA-OP and (ii) one or more boosting inoculations of a second recombinant virus encoding PSA-OP, wherein the first and second recombinant viruses are from a different genus.Type: ApplicationFiled: December 23, 2010Publication date: April 21, 2011Applicant: The USA as represented by the Secretary, Dept. of Health and Human ServicesInventors: Jeffrey Schlom, Kwong-yok Tsang, Sam Zaremba
-
Patent number: 7871986Abstract: The invention provides a prostate specific antigen oligo-epitope peptide (PSA-OP) that is useful as an immunogen in the prevention or treatment of prostatic cancer and in the inhibition of prostatic cancer cells and in the establishment and characterization of PSA-specific cytotoxic T-cell lines. In particular, the invention provides methods for eliciting an immune response against PSA comprising administering (i) a priming inoculation of a first recombinant virus encoding PSA-OP and (ii) one or more boosting inoculations of a second recombinant virus encoding PSA-OP, wherein the first and second recombinant viruses are from a different genus.Type: GrantFiled: June 5, 2009Date of Patent: January 18, 2011Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Jeffrey Schlom, Kwong-Yok Tsang, Sam Zaremba
-
Publication number: 20100209386Abstract: The invention provides a peptide comprising an agonist of a MHC Class I binding native sequence having amino acid substitution(s) and enhanced immunogenicity compared to the native sequence. The invention also provides methods comprising the administration of the peptide.Type: ApplicationFiled: April 1, 2010Publication date: August 19, 2010Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Jeffrey Schlom, Elene Barzaga, Sam Zaremba
-
Patent number: 7723096Abstract: A nucleic acid molecule encoding an amino acid sequence consisting of an agonist of a MHC class I binding native sequence of CEA having an amino acid substitution and enhanced immunogenicity compared to the native sequence is described. A vector comprising the nucleic acid molecule, host cell comprising the vector and a kit comprising the encoded agonist peptide are also described.Type: GrantFiled: December 3, 2003Date of Patent: May 25, 2010Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Jeffrey Schlom, Elene Barzaga, Sam Zaremba
-
Publication number: 20090263425Abstract: The invention provides a prostate specific antigen oligo-epitope peptide (PSA-OP) that is useful as an immunogen in the prevention or treatment of prostatic cancer and in the inhibition of prostatic cancer cells and in the establishment and characterization of PSA-specific cytotoxic T-cell lines. In particular, the invention provides methods for eliciting an immune response against PSA comprising administering (i) a priming inoculation of a first recombinant virus encoding PSA-OP and (ii) one or more boosting inoculations of a second recombinant virus encoding PSA-OP, wherein the first and second recombinant viruses are from a different genus.Type: ApplicationFiled: June 5, 2009Publication date: October 22, 2009Inventors: Jeffrey Schlom, Kwong-yok Tsang, Sam Zaremba
-
Patent number: 7547773Abstract: The invention is a prostate specific antigen oligo-epitope peptide which comprises more than one PSA epitope peptide, which conforms to one or more human HLA class I motifs. The prostate specific antigen oligo-epitope peptide in combination with various HLA-class I molecules or interactions with various T-cell receptors elicits PSA specific cellular immune responses. The prostate specific antigen oligo-epitope peptide is useful as an immunogen in the prevention or treatment of prostatic cancer, in the inhibition of prostatic cancer cells and in the establishment and characterization of PSA-specific cytotoxic T-cell lines.Type: GrantFiled: December 1, 2006Date of Patent: June 16, 2009Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Jeffrey Schlom, Kwong-yok Tsang, Sam Zaremba
-
Publication number: 20070098691Abstract: The invention is a prostate specific antigen oligo-epitope peptide which comprises more than one PSA epitope peptide, which conforms to one or more human HLA class I motifs. The prostate specific antigen oligo-epitope peptide in combination with various HLA-class I molecules or interactions with various T-cell receptors elicits PSA specific cellular immune responses. The prostate specific antigen oligo-epitope peptide is useful as an immunogen in the prevention or treatment of prostatic cancer, in the inhibition of prostatic cancer cells and in the establishment and characterization of PSA-specific cytotoxic T-cell lines.Type: ApplicationFiled: December 1, 2006Publication date: May 3, 2007Applicant: The Govt. of the U.S.A., as represented by the Secretary, Dept. of Health & Human ServicesInventors: Jeffrey Schlom, Kwong-yok Tsang, Sam Zaremba
-
Publication number: 20070048860Abstract: The present invention relates to novel modified CEA agonist (or antagonist) peptides, polypeptides and proteins containing a modified epitope therein, nucleic acids coding therefor, vectors comprising said nucleic acids, mixtures and compositions of the aforementioned agents, and their advantageous use in generating CEA-specific immune responses and/or in the treatment of cancers and the present invention further relates to the foregoing combined with one or more costimulatory molecules.Type: ApplicationFiled: December 30, 2005Publication date: March 1, 2007Applicant: The Government of the USA, as represented by the Secretary, Department of Health and Human ServicesInventors: Jeffrey Schlom, James Hodge, Sam Zaremba, Maria Salazar
-
Publication number: 20060064247Abstract: Provided herein is a method and computer program product for designing and/or simulating a biotechnology experiment in silico; and for providing and generating revenue from a customized list of one or more biotechnology products and/or services related to the in silico designed or simulated biotechnology experiment or the product of that experiment. In illustrative examples, the products and or services are indirectly related to a biomolecule designed by the in silico designed biotechnology experiment. In addition, provided herein is a method and computer system for generating revenue, that includes providing a customer with a first computer program product for designing or performing a biotechnology experiment in silico; and providing the customer with access to a purchase function for purchasing a second computer program product for designing or performing a biotechnology experiment in silico.Type: ApplicationFiled: July 14, 2005Publication date: March 23, 2006Inventors: Shao-Min Yuan, Michael Beltsov, Thomas Chappell, Kevin Clancy, Peter McGarvey, Sam Zaremba, James Caffrey, Konstantin Belov, Anatoliy Mnev, Siamak Baharloo, Aruna Myneni, James Gilmore
-
Patent number: 6946133Abstract: The invention is a prostate specific antigen oligo-epitope peptide which comprises more than one PSA epitope peptide, which conforms to one or more human HLA class I motifs. The prostate specific antigen oligo-epitope peptide in combination with various HLA-class I molecules or interactions with various T-cell receptors elicits PSA specific cellular immune responses. The prostate specific antigen oligo-epitope peptide is useful as an immunogen in the prevention or treatment of prostatic cancer, in the inhibition of prostatic cancer cells and in the establishment and characterization of PSA-specific cytotoxic T-cell lines.Type: GrantFiled: March 20, 1996Date of Patent: September 20, 2005Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Jeffrey Schlom, Kwong-yok Tsang, Sam Zaremba
-
Publication number: 20050196806Abstract: The invention is a prostate specific antigen oligo-epitope peptide which comprises more than one PSA epitope peptide, which conforms to one or more human HLA class I motifs. The prostate specific antigen oligo-epitope peptide in combination with various HLA-class I molecules or interactions with various T-cell receptors elicits PSA specific cellular immune responses. The prostate specific antigen oligo-epitope peptide is useful as an immunogen in the prevention or treatment of prostatic cancer, in the inhibition of prostatic cancer cells and in the establishment and characterization of PSA-specific cytotoxic T-cell lines.Type: ApplicationFiled: April 26, 2005Publication date: September 8, 2005Applicant: The Government of the USA, as represented by the Secretary, Department of Health and Human ServicesInventors: Jeffrey Schlom, Kwong-yok Tsang, Sam Zaremba
-
Publication number: 20040171796Abstract: A peptide comprising an agonist of a MHC Class I binding native sequence having amino acid substitution(s) and enhanced immunogenicity compared to the native sequence is described. Pharmaceutical compositions, peptide-immunoglobulin conjugates, kits and peptide-carrier molecules comprising such peptides also are described.Type: ApplicationFiled: December 3, 2003Publication date: September 2, 2004Applicant: The Government of the USA, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Jeffrey Schlom, Elene Barzaga, Sam Zaremba
-
Patent number: 6756038Abstract: The present invention relates to the preparation and use of peptides that act as agonists and antagonists of human carcinoembryonic antigen (CEA). Agonists of the CEA peptide, CAP1, are disclosed and their utility in enhancing immune responses against CEA demonstrated.Type: GrantFiled: June 13, 2000Date of Patent: June 29, 2004Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Jeffrey Schlom, Elene Barzaga, Sam Zaremba